Author: BHS

Blue Horseshoe Stocks: Revisiting the Cannabis Sector

Marijuana Sector Heating Up Again

Last year at this time, we were in the midst of one of the most exciting times for an individual sector that we’ve ever witnessed. You’ll recall that the 2014 New Year brought the beginning of the first legal recreational marijuana sales in Colorado, and as a result the interest in cannabis and related stocks went absolutely through the roof. The months-long free-for-all was punctuated by dozens of ‘pot plays’ making astronomical gains, and it went down in the books as one of the most exciting mega-trends we’ve ever lived through.

While we don’t expect to see anything of that hype-fueled magnitude this year, we did notice a significant rise in activity in several of the marijuana stocks that we’ve tracked all throughout 2014 ramping up at the end of last week, so we thought this morning would be a good time to call some attention back to the legal/medical cannabis arena.

Friday’s list of gainers read like a symbol-for-symbol recap of our pot stock watchlist. Among those, the most impressive were ones that we are used to seeing make incredible moves:

HEMP, CBIS, MJNA, EAPH, GRNH, MCIG, ERBB, & TRTC 

*If you’d like to inspect our history with each stock, you can check the archives by typing bluehorseshoestocks.com/tag/____  and replacing the blank space with whichever symbol you’d like to pull up. It will furnish you with a chronological listing of each article that we posted on a given stock. (Note that this method can be used for any symbol we’ve ever covered, making us 100% transparent- just another reason why we feel our newsletter is the best around)

We will continue to make the monitoring of the cannabis sector a high priority for us as we settle into the New Year. More and more initiatives are being voted on all the time, and as we’ve been saying since 2012, the legalization of marijuana throughout the United States is going to play out like a domino effect. With measures having passed already in a handful of states, and several more slated to address  various degrees of the issue on impending ballots, the landscape of the industry should be expected to change and grow dramatically into the foreseeable future. Like always, we’ll be ready to capitalize on that growth as it happens.

Energous Corp. WATT

We also want to do a quick follow-up on WATT, a stock that we initially tagged on Wednesday Dec. 24th at a low of 8.40 and the stock has been on an overall uptrend in the five sessions since that time.

On Friday the stock managed to close in the 11.30’s and in the premarket today, we have seen trades go off as high as 12.65; that marks an increase over our observed low totaling 51%, so big congratulations are in order for anyone that has been tracking this play along with us.

There’s also some news out today about an agreement with an established electronics company that could help WATT speed up its wireless charging solution’s path to market. That’s a story we will definitely need to monitor moving forward:

Extended Watchlist:
CEMP, CNAT, STXS, KMDA, URZ, THLD

Blue Horseshoe Stocks: BCLI Recap & More

BrainStorm Cell Therapeutics, Inc. BCLI

2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.

The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.

Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.


RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX

We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.

RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.

NRX saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .

Extended Watchlist:
CUR, ARWR, CLF, MSTX, RAD

Blue Horseshoe Stocks: Final Report of 2014

Good Morning Traders! Here it is- the final report of 2014! We had an amazing year, with huge gainers popping out of the woodwork left, right, and center! We want to take this opportunity to thank all of our readers for being a part of our community, wish you all a Happy New Year while reminding everyone that the best is yet to come… Each year our resolution remains the same: To make the upcoming year our best one ever! We’ve succeeded time and time again, and have no reason to believe that 2015 will be any different so be sure to stay with us! Cheers!

NeuroDerm Ltd. NDRM
NDRM exceeded all expectations yesterday after we caught it on an early morning news scan; it spent the entire day in full-on breakout mode setting records in both price and volume, trading almost 27X the norm over the six week period since the stock’s IPO.

Positive response to yesterday’s early morning press statement hurtled NDRM from an early low of 8.16 all the way up to 19.07 just prior to the close, making gains of up to 134% possible.

We’ll still be standing at the ready for an eventual course correction and chance for a dip-and-rip maneuver, but any way you slice it, NDRM is getting marked down as a huge winner. It’s a great way to close out what has, on the whole, been an absolutely stellar year.

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)

Precious Metals on Watch: Gold, Silver

GDX and SLV have each been maintaining higher highs and higher lows since reaching a bottom in November. As we head into the New Year, we’re going to devote a good amount of focus to gold and silver, and tracking these indices and their options chains is going to be a good way to do that.

In particular, we’re going to be monitoring a few specific sets of contracts for each play:

  SLV – March $15-15.50 Calls

GDX – March $17.50-$18 Calls

As you can see from the side-by-side chart we drew up below, GDX and SLV are looking similarly ripe. We’ve got SLV breaking the 50-Line on the RSI, and GDX following closely behind in that regard, we’re seeing testing of the 50DMA’s on both charts, and each of the MACD’s are giving the indication of bullish crosses.

Side Note:
We’re also going to radar HMCP, a sub-penny momentum play that has had an interesting past few sessions.

Extended Watchlist:
NRX, RDHL, MIG, CYTK, NEON, BCLI, CVEO